I'm over 40, and I swear by these Amazon Prime Day beauty deals to delay the signs of aging
Thankfully, Underscored's beauty editor and deals team have sourced all the best Prime Day deals, making it easy to snag my favorite beauty products at a discount or try out new ones without breaking the bank. Here are the beauty items I swear by (and some I'm trying for the first time) for keeping signs of aging at bay.
Medicube Age-R Booster Pro Beauty Massager
I bought this during Cyber Monday after listening to our beauty editor Sophie Shaw rave about how good it is at improving complexion and tightening skin. As always, she was right. I've seen a visible difference in the surface and elasticity of my skin, especially around my jowls, and have recommended it to all my friends. At up to 34% off for Prime Day, it is well worth the splurge.
Braun Skin i-Expert IPL Device
I have neither the time nor the inclination to go for regular hair removal appointments, and after going back and forth to a salon for expensive laser treatments last year, I decided enough was enough and pulled the trigger on this magical device. Now this DIY version tackles all my hair-removing needs. Yes, it's pricey, but it will save you a ton of money over time.Read our review
Viviscal Thickening Shampoo
I used to complain constantly about having thick hair when I was younger (oh, how foolish I was). After years of constant damage, two bouts of grief-induced stress and simply getting older, my hair was seriously thinning out and breaking more than ever before. After using this shampoo for two months, I noticed I was losing less hair in the shower and the amount of breakage was drastically reduced. Now I only use this once or twice a week for maintenance, but it's still effective. I've stocked up on a few bottles this Prime Day.
Waterpik Cordless Advanced 2.0 Water Flosser
Our teeth get more brittle and our enamel gets weaker as we age. Add to that the fact I have receding gums and my dentist told me a few years ago that brushing and flossing was not going to cut it anymore. So I added a Waterpik to my oral hygiene routine, and I can honestly say that I love using it. It's crazy how much food it removes even after I've flossed. Believe me when I say, you'll save thousands at the dentist.
Color Wow Dream Coat Supernatural Spray
This hair care product needs no introduction. Loved by celebrity hair stylists and everyone at CNN Underscored, this is my secret weapon for smoothing frizzy hair and keeping humidity at bay, especially in this crazy summer heat. Once you try it, you'll fall in love.
Biodance Bio-Collagen Real Deep Mask, 4-Pack
I haven't tried these yet, but folks on the team swear by them. Now that they're 30% off for a four-pack, I figure now is as good a time as any to give them a go. With almost 20,000 reviews on Amazon (most of them 5 stars) and plenty of testimonials on TikTok, I have a feeling I won't be disappointed. Read our review
Estée Lauder Advanced Night Repair Face Serum
My mom used this her whole life and looked 15 years younger than she actually was. I would 'borrow' it from her nightstand while she wasn't looking, and I knew even then it was a splurge. This is another celeb-loved product and rarely goes on sale, so you better believe I stock up anytime it does have a discount. The 35% discount on the 1.7-ounce bottle is the best I've seen in a while.
La Roche Posay Pure Vitamin C12 Serum
Another popular brand when I was growing up, La Roche Posay is still as buzzy as ever, simply because it works. Vitamin C serum is a must-have in any beauty routine. I put this one on after cleansing every morning and night.
Patchology FlashPatch Restoring Night Eye Gels
Under-eye patches are a must in anyone's beauty or grooming routine, since the eyes are the window to the soul (and your age!). The skin under the eye is more delicate than the rest of the face so needs extra attention. I swear by these restoring patches from Patchology to reduce puffiness and brighten dark circles.
Medicube Collagen Overnight Wrapping Mask
This was recommended by a colleague earlier this year, and I absolutely love it. It feels weird at first to sleep with it on, but it's worth it in the morning, as it gives that glass skin look I'm seeing all over social media. And who doesn't love the satisfying feeling of peeling off a mask to reveal brighter-looking skin?
Eucerin Advanced Repair Hand Cream, 3-Pack
My hands have always been super dry, so I take hand cream with me wherever I go. Every night, I slather on Eucerin's Advanced Repair cream to keep them moisturized through the night so they feel really soft in the morning. Hands can be a telltale sign of aging, so it's important not to neglect them, regardless of your age or skin type.
Qure LED Face Mask
I haven't tried this yet, and I've been holding off on buying an LED mask despite the fact everyone in the office seems to have one. But I use Qure's at-home Microinfusion System (sadly, it's not on sale for Prime Day), and I couldn't believe the difference in my skin tone, so I'm a fan of the brand. What interests me about trying this mask is that it uses both red and blue light therapy to treat inflammation, protect collagen and reduce breakouts.
Sol de Janeiro Delícia Drench Body Butter
The skin on your body is just as important as the skin on your face. There's nothing quite like a crepey décolletage to show your true age — no matter how good your face looks. I slather Sol de Janeiro's body butter all over after I shower, and it keeps my skin smooth and smelling good.
Crest Professional Effects 3D Whitestrips Dental Whitening Kit, 44-Pack
I stock up on Crest Whitestrips during Prime Day as they're always at such a great discount. I'm a coffee fiend and enjoy the occasional glass of red wine, so I use these fairly regularly to keep my teeth looking pearly white while still enjoying those indulgences.
PMD Personal Microderm Elite Pro With Starter Kit
I use this tool once a week for some deep-cleaning magic. The suction mode cleans out my pores, while the exfoliation discs help to brighten my complexion and even out my skin tone. I started to see a real difference after just six weeks of use. When I saw it was almost 50% off for the set, I sent the link to several of my friends. It's really that good. There are thousands upon thousands of deals on Amazon during Prime Day, and it's hard to know what is really a true deal or not. Here at CNN Underscored, we only feature really good deals by checking price comparison tools as well as our own research. Most of the products featured here are Amazon beauty deals I've bought in the past. I'm always on the lookout for a bargain since beauty products can be expensive — though they don't have to be.
CNN Underscored has a team of skilled writers and editors who have many years of experience testing, researching and recommending products, and they ensure each article is carefully edited and products are properly vetted. This story was written by CNN Underscored managing editor Rachel Quigley who has been a writer or editor for almost 20 years and has covered beauty for more than five years. Since turning 40, she is dedicated to finding beauty products and devices that actually work as she fights the signs of aging.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Fox News
13 minutes ago
- Fox News
Actress reveals how cancer test that saved her life led to surprising family discovery
Olivia Munn, who previously claimed that a breast cancer risk assessment test saved her life, announced on social media this week that it also saved her mother's life. "My mother was diagnosed with breast cancer," the actress, 45, wrote in her caption. "You may know that when I talk about my own battle with cancer, I bring up the Lifetime Risk Assessment test that saved my life. I never would've predicted it would save my mom's life as well." While there are several risk assessment tools available to patients and physicians, the breast cancer risk assessment tool (BCRAT) is one of the most common, Fox News Digital previously reported. The BCRAT is based on a statistical model known as the Gail Model. It's named after Dr. Mitchell Gail, an NIH distinguished investigator at the National Cancer Institute, according to a National Cancer Institute (NCI) spokesperson. The five-minute test helps predict a woman's risk of developing invasive breast cancer within the next five years, and up to 90 years of age, according to the NCI. Just one year ago, Munn credited the test with prompting her to get a biopsy – even after mammograms and genetic testing came back negative. The biopsy showed she had Luminal B cancer in both breasts. Luminal B is an aggressive, fast-moving cancer. The BCRAT calculates a woman's "absolute breast cancer risk." On its website, the organization defines this as the "chance or probability of developing invasive breast cancer in a defined age interval." The risk calculator considers factors including age, race, medical history and reproductive history. It also looks at the family history of breast cancer among relatives like mothers, sisters and daughters. Once the information is calculated, users are provided with a score. Fox News Digital previously reported that a five-year risk score of 1.67% or more is considered high-risk. A healthcare provider may recommend certain medications to decrease the chances of developing cancer, according to Cleveland Clinic's website. For more Health articles, visit Dr. Nicole Saphier, M.D., board-certified breast imaging radiologist and associate professor at Memorial Sloan Kettering Cancer Center in New York City, recommends individual risk assessments to her referring clinicians and patients. "Olivia Munn's doctor may have saved her life by doing so," Saphier previously said in a statement to Fox News Digital when news of Munn's diagnosis first broke in 2024. "While a standard mammogram is sufficient for nearly half of all women, many others will benefit from adding an ultrasound or MRI based on breast density and various other factors that may make someone [a] higher risk [candidate]." Less than 5% of all women diagnosed with breast cancer will have cancer in the contralateral (opposite) breast, according to Saphier. "Olivia Munn was one of those rare cases," she said.
Medscape
37 minutes ago
- Medscape
Cannabis Cuts Migraine in First Placebo-Controlled Trial
MINNEAPOLIS — In the first placebo-controlled trial of vaporized cannabis for acute migraine, patients experienced greater relief from pain and other symptoms than those receiving a placebo. During a migraine attack, participants who inhaled a combination of tetrahydrocannabinol (THC) and cannabidiol (CBD) reported significant pain reduction and improvement in their most bothersome symptom within 2 hours of treatment. The findings suggest that a THC-CBD combination may offer a viable treatment option for acute migraine in patients who do not respond to standard therapies, study investigator Nathaniel M. Schuster, MD, pain and headache neurologist and associate professor of anesthesiology at the UC San Diego (UCSD) Health Center for Pain Medicine, told Medscape Medical News . 'This is the first placebo-controlled study in this space. It's the first real — to me — compelling evidence for the antimigraine effects of cannabis in humans,' he said. The findings were presented here at the American Headache Society (AHS) Annual Meeting 2025. Undisclosed Cannabis Use Common Some patients are likely already using cannabis to self-medicate during migraine attacks, Schuster noted. He pointed to a recent cross-sectional survey showing that 31.0% of individuals with chronic pain reported using cannabis for pain relief. In another cross-sectional study of 1429 medical cannabis users, 61.2% reported they used it specifically to manage chronic pain. Schuster noted that cannabis use may be even more common among those with migraine. However, patients often don't disclose cannabis use to their physicians. Uncertain about how their doctors might react, some individuals may choose to self-medicate or combine cannabis with prescribed treatments without informing healthcare providers. To determine the efficacy of vaporized cannabis for acute migraine, the investigators conducted a randomized, double-blind, placebo-controlled crossover trial. It included 92 patients with a history of migraine with or without aura who received treatment for a moderate-to-severe migraine attack using vaporized cannabis or a placebo between November 2020 and February 2023. With respect to cannabis use, 37 (40.2%) of study participants reported they had used it within the past year, 21 (22.9%) more than a year ago, and 33 (35.9%) had never used it. Participants had a median age of 41 years, with the majority being women (82.6%). Participants had a median onset age of 20 years, with a median of 15 headache days and six migraine days per month. In addition, 30.4% had chronic migraine. For each migraine attack, patients received one of four randomized treatments: 6% THC, 11% CBD, a combination of 6% THC and 11% CBD, or a placebo. All cannabis was provided through the National Institute on Drug Abuse Drug Supply Program. Instructions for using vaporized cannabis were provided by a research coordinator during the screening visit and reinforced through a custom smartphone app, which also captured real-time data on outcomes and safety events. Patients self-administered the treatment or placebo using the Foltin Uniform Puff Procedure with the vaporizer. Patients were not permitted to use any migraine treatment before the onset of an attack but were permitted to use standard acute therapy as a rescue medication if needed after 2 hours. They were also prohibited from repeating the cannabis dose before reporting outcomes at the 2-hour mark. The study's primary outcome was pain relief at 2 hours. Secondary outcomes included pain freedom and relief from the most bothersome symptom at the same timepoint. Patients also recorded improvements in photophobia, phonophobia, nausea, and vomiting, as well as sustained pain and symptom freedom out to 48 hours. Overall, 73 patients experienced at least one migraine attack. This included 52 patients with four attacks, six with three attacks, six with two attacks, and nine with a single attack. Efficacy and Tolerability A total of 247 migraine attacks were included in the intent-to-treat analysis, with 234 attacks providing 2-hour outcome data for the modified intent-to-treat analysis. Among these 234 treated attacks, patients identified photophobia as the most bothersome symptom in 137 cases (58.5%), nausea in 60 cases (25.6%), and phonophobia in 37 cases (15.8%). At 2 hours, 68.9% of patients in the THC group, 67.2% in the THC/CBD group, 52.6% in the CBD group, and 46.6% in the placebo group reported pain relief. Both the THC group (odds ratio [OR], 2.846; 95% CI, 1.218-6.652; P = .008) and the THC/CBD group (OR, 2.846; 95% CI, 1.218-6.652; P = .016) showed significantly greater pain relief than the placebo group. The 2-hour pain freedom was achieved by 34.5% of patients in the THC/CBD group, 27.9% in the THC group, 22.8% in the CBD group, and 15.5% in the placebo group. The THC/CBD group had significantly improved 2-hour pain freedom compared with the placebo group (OR, 3.295; 95% CI, 1.235-8.795; P = .017). Freedom from the most bothersome symptom at 2 hours was also significantly higher in the THC/CBD group than the placebo group (60.3% vs 34.5%; OR, 3.332; 95% CI, 1.445-7.637; P = .005), but not in the THC (47.5%) or CBD (42.1%) groups. Compared with the placebo group, the THC/CBD group also had significantly higher rates of sustained pain relief and symptom freedom up to 24 and 48 hours. Improvements were also seen in photophobia (56.9% vs 37.9%) and phonophobia (74.1% vs 51.7%), though there were no significant differences in relief from nausea at 2 hours or vomiting at 48 hours. Schuster noted initial concern that the observed effect on the most bothersome symptoms might be driven primarily by nausea relief, rather than a broader symptom response. 'That's certainly not what we found. What we found is that it does have effects on the photophobia and phonophobia, and that's an important finding,' he said. At 1 hour, sleepiness was more common in the THC (41.4%), THC/CBD (44.6%), and CBD (37.5%) groups compared with the placebo group (26.7%). Euphoria was also more frequently reported in the THC (36.2%) and THC/CBD (28.6%) groups compared with the CBD (8.9%) and placebo (7%) groups. Cognitive impairment followed a similar pattern, with higher rates in the THC (34.5%) and THC/CBD (21.4%) groups than in the CBD (14.3%) and placebo (7%) groups. By 2 hours, sleepiness increased across all groups, with rates highest in the CBD group (50.9%), followed by the THC (42.6%), placebo (37.9%), and THC/CBD (31.0%) groups. No Serious Adverse Events At 2 hours, rates of euphoria were lower than at 1 hour but remained higher in the THC (26.2%) and THC/CBD (12.1%) groups than in the CBD (7.0%) and placebo (5.2%) groups. Similarly, cognitive impairment was more common in the THC (26.2%) and THC/CBD (12.1%) groups than in the CBD (7.0%) and placebo (5.2%) groups. The fact that the THC group had a higher rate of euphoria and cognitive impairment than the THC/CBD group was an expected finding. 'It's known that CBD is a noncompetitive, negative allosteric modulator of the CB-1 [cannabinoid receptor 1] receptor that decreases the psychoactive side effects of the THC,' Schuster said. Patients rated their level of intoxication on a 0-10 scale at 1 and 2 hours post-treatment. At 1 hour, the THC group reported an average intoxication rating of 3.5; the THC/CBD group, 2.4; the CBD group, 1.5; and the placebo group, 0.6. By 2 hours, all groups reported reduced intoxication levels: THC at 2.4, THC/CBD at 1.3, CBD at 0.9, and placebo at 0.4. Schuster noted that patients can experience therapeutic benefits for migraine without needing to use recreational-level doses. At 1 hour, adverse events were reported by 31.0% of patients in the THC group, 19.6% in both the THC/CBD and CBD groups, and 5.0% in the placebo group. By 2 hours, rates declined to 18.0% in the THC group, 6.9% in the THC/CBD group, 7.0% in the CBD group, and 5.2% in the placebo group. The most common side effects — sedation and slowness — were primarily reported in the THC-containing groups. The researchers reported no serious adverse events, which Schuster noted was a potential concern. However, there were no reports of paranoia, dysphoria, after-hours calls, or emergency room visits in the study, he said. At 2 hours, 29.3% of patients believed they had received the placebo, 20.7% thought they received the THC/CBD combination, 13.1% guessed THC, and 10.5% guessed CBD. Meanwhile, 49.2% of patients correctly identified they had received THC, and 46.6% correctly identified the THC/CBD combination. What to Tell Patients Patients who have never used other acute treatments should start with standard-of-care treatments, such as a triptan or calcitonin gene-related peptide inhibitor, before looking to cannabis as an option, Schuster said. When counseling patients who ask about cannabis or report cannabis use, neurologists should consider that the THC/CBD arm of the study showed a similar effect to THC alone with fewer side effects. Another consideration is that the study used vaporized cannabis flower, which is seen as a safer option than waxes, oils, and smoking cannabis, he said. It is also important to not overuse cannabis as an acute migraine treatment, he noted. 'A lot of neurologists, myself included, suspect that there could be medication overuse headache with [using] cannabinoids frequently,' he said. 'When I counsel patients now, I say, 'Look, we were only studying infrequent — four times over the course of a year — administration.' So, I encourage patients to certainly limit it to under 10 times per month and to optimally be using it really for those migraines that would not respond to standard-of-care therapy,' he added. More Research Needed Commenting on the research for Medscape Medical News , Amaal J. Starling, MD, associate professor of neurology at the Mayo Clinic in Phoenix, said that the efficacy and safety of cannabis as a migraine treatment are not well understood. 'Even though THC/CBD use for the treatment of migraine is a popular topic for patients, there is a paucity of robust clinical trials on this topic. However, people are using cannabis to treat migraine and migraine symptoms, like nausea,' she said. Starling said the blinding analysis was a strength and noted that patients did not appear to be able to guess whether they had received cannabis despite having used it before. While the study found THC and THC/CBD together improved migraine pain compared with a placebo group, there was a high rate of side effects, and it was a single-center study. 'Generalizability of efficacy and consistency of efficacy are still unknown,' she said. 'We need additional studies to replicate this work in larger populations. In addition, we need to know the longer-term implications of cannabis use for the treatment of migraine,' she added.
Bloomberg
an hour ago
- Bloomberg
Moderna's Covid Shot Fully Approved by FDA for Use in Children
US regulators approved Moderna Inc. 's Covid vaccine for children, a positive sign for the company amid Robert F. Kennedy Jr.'s controversial policy positions that have led to restricted access to the shots for kids. The Food and Drug Administration cleared the company's application for full approval of the immunization for kids under 12 who are at increased risk from the disease, the company said in a statement.
